Search

Author/Creator Kosoglou, Teddy

1. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study . (1st July 2020)

Authors:
O'Neil, Brian; Ison, Michael G; Hallouin-Bernard, Marie Charlotte; Nilsson, Anna C; Torres, Antoni; Wilburn, John M; van Duijnhoven, Wilbert; Van Dromme, Ilse; Anderson, David; Deleu, Sofie; Kosoglou, Teddy; Vingerhoets, Johan; Rossenu, Stefaan; Leopold, Lorant
Journal:
Journal of infectious diseases
Issue:
Volume 226:Number 1(2022)
Page Start:
109
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered‐dose inhaler versus an MF dry‐powder inhaler in healthy subjects. Issue 3 (10th February 2014)

Authors:
Kosoglou, Teddy; Hubbell, James; Kantesaria, Bhavna; Hanson, Mary E.; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 3:Issue 3(2014:May/Jun.)
Page Start:
229
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers. Issue 3 (14th May 2013)

Authors:
Kosoglou, Teddy; Reyderman, Larisa; Tseng, Jack; Kumar, Bharath; Xuan, Fengjuan; Schiller, James; Meehan, Alan G.; Kim, Kenneth; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 2:Issue 3(2013:Jul.)
Page Start:
223
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Effect of the thrombin receptor antagonist (PAR‐1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo‐ and positive‐controlled, parallel group trial. Issue 1 (25th September 2013)

Authors:
Kosoglou, Teddy; Hunt, Thomas L.; Xuan, Fengjuan; Kumar, Bharath; Statkevich, Paul; Hanson, Mary E.; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 3:Issue 1(2014:Jan./Feb.)
Page Start:
18
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed‐dose combination metered‐dose inhaler device. Issue 3 (18th February 2014)

Authors:
Kosoglou, Teddy; Hubbell, James; Johnson‐Levonas, Amy O.; Yunan, Mona; Kantesaria, Bhavna S.; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 3:Issue 3(2014:May/Jun.)
Page Start:
222
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers. Issue 2 (12th April 2017)

Authors:
Anderson, Matt S.; Kosoglou, Teddy; Statkevich, Paul; Li, Jing; Rotonda, Jennifer; Meehan, Alan G.; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 7:Issue 2(2018)
Page Start:
143
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. (14th November 2018)

Authors:
Finberg, Robert W; Lanno, Riin; Anderson, David; Fleischhackl, Roman; van Duijnhoven, Wilbert; Kauffman, Robert S; Kosoglou, Teddy; Vingerhoets, Johan; Leopold, Lorant
Journal:
Journal of infectious diseases
Issue:
Volume 219:Number 7(2019)
Page Start:
1026
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR‐1 Antagonist, in Healthy Adult Subjects. Issue 4 (8th October 2013)

Authors:
Behm, Martin O.; Kosoglou, Teddy; Miltenburg, André M.M.; Li, Jing; Statkevich, Paul; Johnson‐Levonas, Amy O.; Martinho, Monika; Fackler, Paul
Journal:
Clinical pharmacology in drug development
Issue:
Volume 2:Issue 4(2013:Oct.)
Page Start:
310
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single‐ and Multiple‐Dose Pharmacokinetics of Vorapaxar1. (20th February 2013)

Authors:
Kosoglou, Teddy; Statkevich, Paul; Kumar, Bharath; Xuan, Fengjuan; Schiller, James E.; Johnson‐Levonas, Amy O.; Young, Sophia; Cutler, David L.
Journal:
Journal of clinical pharmacology
Issue:
Volume 53:Number 5(2013:May)
Page Start:
540
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. The Influence of Multiple‐Dose Vorapaxar, an Oral PAR‐1 Receptor Antagonist, on the Single‐Dose Pharmacokinetics and Pharmacodynamics of Digoxin. Issue 1 (26th February 2013)

Authors:
Kosoglou, Teddy; Zhu, Yali; Statkevich, Paul; Xuan, Fengjuan; Schiller, James E.; Johnson‐Levonas, Amy O.; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 2:Issue 1(2013:Jan.)
Page Start:
90
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗